This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morgan, M. A. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Morgan, M. A. Articles by Lawrence, T. S.

Role of Checkpoint Kinase 1 in Preventing Premature Mitosis in Response to Gemcitabine

Departments of ¹ Radiation Oncology and ² Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan

Requests for reprints: Theodore S. Lawrence, Department of Radiation Oncology, University of Michigan Medical Center, UH-B2C490, Box 0010, 1500 East Medical Center Drive, Ann Arbor, MI 49109-0010. Phone: 734-647-9955; Fax: 734-763-7371; E-mail: tsl{at}med.umich.edu.

The deoxycytidine analogue 2',2'-difluoro-2'-deoxycytidine (gemcitabine) is a potent radiation sensitizer in a variety of solid tumors and tumor cell lines. Previous studies have shown that radiosensitization by gemcitabine is accompanied by simultaneous depletion of dATP pools (through ribonucleotide reductase inhibition) and accumulation in the S-phase of the cell cycle. Because of the importance of cell cycle redistribution in gemcitabine-mediated radiosensitization, we investigated the role of checkpoint kinase (Chk) 1 and Chk2 in gemcitabine-induced cell cycle arrest. We hypothesized that gemcitabine might induce Chk1 or Chk2 signal transduction pathways that mediate S-phase arrest. We found that radiosensitizing concentrations of gemcitabine induced accumulation of phosphorylated Chk1 and Chk2 and down-regulation of Cdc25A in BxPC-3 (10 nmol/L), Panc-1 (100 nmol/L), A549 (30 nmol/L), RKO (30 nmol/L), and SW620 (30 nmol/L) cells. Depletion of Chk1 from Panc-1 cells prevented the down-regulation of Cdc25A in response to gemcitabine. Furthermore, Chk1 depletion permitted Panc-1 and SW620 cells treated with gemcitabine to enter mitosis despite incomplete DNA synthesis. However, depletion of neither Chk1 nor Chk2 abrogated the inhibition of DNA synthesis in response to gemcitabine. These results provide evidence that Chk1 negatively regulates entry into mitosis in response to gemcitabine. Furthermore, these data imply that Chk1 acts to coordinate the cell cycle with DNA synthesis, thus preventing premature mitotic entry in gemcitabine-treated cells.

This article has been cited by other articles:

				S. D. Zabludoff, C. Deng, M. R. Grondine, A. M. Sheehy, S. Ashwell, B. L. Caleb, S. Green, H. R. Haye, C. L. Horn, J. W. Janetka, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol. Cancer Ther., September 1, 2008; 7(9): 2955 - 2966. [Abstract] [Full Text] [PDF]

				M. Galvez-Peralta, N. T. Dai, D. A. Loegering, K. S. Flatten, S. L. Safgren, J. M. Wagner, M. M. Ames, L. M. Karnitz, and S. H. Kaufmann Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines Mol. Pharmacol., September 1, 2008; 74(3): 724 - 735. [Abstract] [Full Text] [PDF]

				T. Okazaki, L. Jiao, P. Chang, D. B. Evans, J. L. Abbruzzese, and D. Li Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer Clin. Cancer Res., April 1, 2008; 14(7): 2042 - 2048. [Abstract] [Full Text] [PDF]

				T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921. [Abstract] [PDF]

				P. Y. Chun, F. Y. Feng, A. M. Scheurer, M. A. Davis, T. S. Lawrence, and M. K. Nyati Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma Cancer Res., January 15, 2006; 66(2): 981 - 988. [Abstract] [Full Text] [PDF]